LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of "Moderate Buy" from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $94.57.

LMAT has been the subject of several recent research reports. Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. Oppenheimer reissued an "outperform" rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a report on Tuesday, August 20th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target for the company. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st.

LeMaitre Vascular Stock Up 0.4 %

Shares of LeMaitre Vascular stock traded up $0.37 on Thursday, hitting $105.80. The company's stock had a trading volume of 86,898 shares, compared to its average volume of 124,239. The company has a market capitalization of $2.38 billion, a P/E ratio of 57.81, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. LeMaitre Vascular has a 52-week low of $51.70 and a 52-week high of $109.58. The firm has a fifty day moving average price of $94.86 and a 200-day moving average price of $87.55.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the prior year, the business earned $0.33 earnings per share. The company's quarterly revenue was up 15.6% on a year-over-year basis. As a group, analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company's stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA lifted its stake in shares of LeMaitre Vascular by 1.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier's stock valued at $976,000 after purchasing an additional 136 shares in the last quarter. Summit Global Investments lifted its position in LeMaitre Vascular by 2.4% during the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock valued at $575,000 after buying an additional 146 shares in the last quarter. Shaker Investments LLC OH grew its stake in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier's stock worth $1,138,000 after buying an additional 175 shares during the period. NBC Securities Inc. increased its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 183 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock valued at $68,000 after acquiring an additional 188 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.